News

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
Moderna falls on doubts over new CDC panel's backing of RSV vaccine
Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
Moderna RSV Vaccine Gets Expanded FDA Approval, Company Says
Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease ...
FDA OKs new Moderna COVID-19 vaccine for 65+, others with conditions
The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...
Moderna Pulls FDA Application for Flu-Covid Combo Vaccine
Moderna has withdrawn its pending application for a combination vaccine for both the flu and Covid-19, saying it will resubmit later this year once it has more data.